US Drug Patent 11,311,488: Claim Scope, Exclusivity, Orange Book Status, and Generic Entry Risk for Deutetrabenazine
US Patent No. 11,311,488 protects a once-daily osmotic oral dosage form containing deutetrabenazine microparticles. Its core coverage combines a two-layer osmotic tablet, a semipermeable membrane and delivery port, controlled particle size, an immediate-release drug fraction, specified drug distribution between layers, and defined pharmacokinetic or dissolution performance. The patent is directed to the extended-release delivery system used for once-daily deutetrabenazine, rather than to deutetrabenazine itself.
The commercial product most closely associated with this technology is Austedo XR, Teva Pharmaceuticals' once-daily formulation of deutetrabenazine. FDA approved Austedo XR in February 2023 for chorea associated with Huntington's disease and tardive dyskinesia. [1]
What does US Patent 11,311,488 protect?
The patent's independent claims protect both the dosage form and methods of treatment.
| Claim group |
Protected subject matter |
Commercial significance |
| Claim 1 |
Once-daily osmotic oral dosage form |
Primary formulation claim |
| Claims 2-20 |
Polymer, osmotic agent, coating, membrane, port, particle-size and loading limitations |
Narrower fallback claims |
| Claim 21 |
Treating a hyperkinetic movement disorder with the dosage form |
Independent method claim |
| Claims 22-27 |
Specific disorders, doses and pharmacokinetic profiles |
Clinical-use and performance claims |
| Claim 28 |
Dissolution limits under specified USP II conditions |
In-vitro performance claim |
The broadest claim requires all of the following:
- A tablet core with an active layer and a push layer.
- Deutetrabenazine microparticles in the active layer.
- An osmotic agent and control-release polymer in the push layer.
- A semipermeable membrane around the core.
- A delivery port extending into the tablet core.
- A total dose of approximately 6 mg to 48 mg.
- Microparticle size parameters of D90 approximately 15 micrometers, D50 approximately 10 micrometers, and/or D10 approximately 3 micrometers.
- Approximately 70% to 80% of the microparticles in the active layer.
- Approximately 20% to 30% in an immediate-release external coating, where that coating is present.
The independent dosage-form claim therefore has broad functional coverage but a technically demanding combination of limitations. A competing product that uses a non-osmotic matrix tablet, a capsule, a multiparticulate system or a materially different drug-release mechanism would have a stronger non-infringement position.
How does the osmotic dosage-form technology work?
The claimed tablet uses an elementary osmotic pump architecture.
Active layer
The active layer contains deutetrabenazine microparticles and a release-control agent. Dependent claims identify polyethylene oxide having an average molecular weight of 100,000 to 500,000 daltons, present at approximately 60% to 98% by weight of the active layer.
The active layer may also contain:
- An antioxidant at approximately 0.001% to 1% by weight.
- A binder at approximately 2% to 20% by weight.
- A polymer with viscosity of approximately 50 to 150 mPa·s, or 55 to 90 mPa·s.
These limitations are important because the active layer must provide controlled drug displacement while preserving the physical integrity of the tablet during hydration.
Push layer
The push layer generates osmotic expansion and forces the hydrated active layer through the delivery port. The claims cover inorganic salts, carbohydrates or mixtures as osmotic agents.
Claim 6 identifies salts including:
- Magnesium sulfate
- Magnesium chloride
- Potassium sulfate
- Sodium chloride
- Sodium sulfate
- Lithium sulfate
- Sodium phosphate
- Potassium phosphate
The push layer control-release polymer has a claimed viscosity of approximately 5,500 to 7,500 mPa·s and is present at approximately 50% to 80% by weight of the push layer. Claim 8 specifies an osmotic-agent-to-control-polymer ratio of 1:2 to 1:3.5, with a narrower range of 1:2 to 1:2.5.
Semipermeable membrane and port
The tablet core is surrounded by a semipermeable layer. The membrane may include cellulose acetate, cellulose diacetate, cellulose triacetate, ethyl cellulose and other water-insoluble or selectively permeable polymers.
The membrane may contain a pore-forming agent, such as a water-soluble sugar, salt, solvent or polymer, at approximately 0.1% to 20% of the membrane weight. The claimed membrane-to-core weight ratio is approximately 1:8 to 1:10. The port diameter is approximately 0.1 mm to 1 mm.
These limitations distinguish the claimed device from ordinary extended-release tablets. The membrane controls water influx, while the port controls drug-containing gel extrusion.
What formulations are protected by US 11,311,488?
The patent protects a specific distribution of deutetrabenazine between the controlled-release core and the immediate-release coating.
| Total deutetrabenazine dose |
Claimed immediate-release loading |
Claimed total microparticle loading |
| 6 mg |
Approximately 0.1% to 0.5% of total dosage-form weight |
Approximately 0.5% to 3% |
| 12 mg |
Approximately 0.5% to 1% |
Approximately 1% to 5% |
| 24 mg |
Approximately 1% to 2% |
Approximately 5% to 10% |
| 36 mg |
Covered by the broader 6 mg to 48 mg range |
Covered by claim 1 |
| 48 mg |
Covered by the broader 6 mg to 48 mg range |
Covered by claim 1 |
Claim 1 states that approximately 70% to 80% of the drug microparticles are in the active layer and approximately 20% to 30% are in the immediate-release coating. Claim 18 separately recites an immediate-release coating containing approximately 0.1% to 30% deutetrabenazine microparticles by total dosage-form weight, with narrower alternatives of 0.2% to 5% and 0.3% to 2%.
The immediate-release component likely addresses early drug exposure, while the osmotic core produces the extended-release portion. A generic developer could attempt to avoid this coverage by eliminating the immediate-release coating, changing the drug distribution, or using a different loading architecture.
How strong is the patent estate for once-daily deutetrabenazine?
The strength of US 11,311,488 is highest against a product that copies the same delivery architecture and dose profile. It is weaker against products that achieve once-daily exposure through a different formulation platform.
Strength factors
The patent has several cumulative technical limitations:
- Two-layer osmotic core.
- Semipermeable membrane.
- Defined port geometry.
- Deutetrabenazine microparticle size.
- Defined immediate-release and controlled-release fractions.
- Specified polymer viscosities and molecular-weight ranges.
- Dose-specific composition ranges.
- Pharmacokinetic and dissolution limitations.
These features can make design-around more difficult when the commercial target is a once-daily formulation with similar exposure and tolerability.
Weakness factors
The claim structure also creates potential validity and enforcement issues:
- Many numerical ranges are broad and overlap with conventional osmotic-pump formulation practice.
- Osmotic tablets, push layers, semipermeable membranes and delivery ports were established technologies before the claimed priority date.
- Microparticle size ranges may be difficult to distinguish from routine particle engineering.
- Claims 23 through 27 rely on pharmacokinetic results that may be difficult to prove from public product testing alone.
- Claim 28 depends on a specified dissolution method, buffer, volume, pH and time point. Testing variation may affect infringement analysis.
- A competitor can potentially avoid literal infringement by changing one required limitation, provided the altered feature is material and the doctrine of equivalents does not apply.
The patent is therefore strongest as a product-by-process-like combination claim against a close copy and less certain as a platform patent covering every once-daily deutetrabenazine formulation.
What do claims 21 through 28 add?
Claims 21 through 28 create a second enforcement pathway based on treatment methods and product performance.
Method-of-use coverage
Claim 21 covers once-daily oral administration for a hyperkinetic movement disorder. Claim 22 identifies:
- Chorea
- Akathisia
- Dyskinesia
- Tremor
- Tic disorders
- Huntington's disease-associated chorea
- Tardive dyskinesia
- Tourette syndrome-associated tics
- Parkinson's disease levodopa-induced dyskinesia
- Dyskinesia in cerebral palsy
The commercial relevance is narrower than the textual scope because FDA-approved labeling determines the approved-use market. Austedo XR is approved for Huntington's disease-associated chorea and tardive dyskinesia, while broader unapproved uses may raise separate regulatory and inducement issues. [1]
Pharmacokinetic limitations
Claims 23 through 27 tie specific doses to exposure of total alpha- and beta-dihydrodeutetrabenazine metabolites. The claims use AUC and Cmax ranges for single-dose and steady-state administration.
| Dose addressed |
Single-dose exposure limits |
Steady-state exposure limits |
| 6 mg |
AUC approximately 91,250 to 142,750 h·pg/mL; Cmax below approximately 4,600 pg/mL in one alternative |
AUC approximately 102,500 to 200,000 h·pg/mL; Cmax below approximately 10,000 pg/mL |
| 12 mg |
AUC approximately 182,500 to 285,500 h·pg/mL; Cmax below approximately 9,200 pg/mL |
AUC approximately 205,000 to 400,000 h·pg/mL; Cmax below approximately 20,000 pg/mL |
| 24 mg |
AUC approximately 365,000 to 571,000 h·pg/mL; Cmax below approximately 18,400 pg/mL |
AUC approximately 410,000 to 800,000 h·pg/mL; Cmax below approximately 40,000 pg/mL |
| 36 mg |
AUC approximately 547,500 to 856,500 h·pg/mL; Cmax below approximately 27,600 pg/mL |
AUC approximately 615,000 to 1,200,000 h·pg/mL; Cmax below approximately 60,000 pg/mL |
| 48 mg |
AUC approximately 730,000 to 1,142,000 h·pg/mL; Cmax below approximately 36,800 pg/mL |
AUC approximately 820,000 to 1,600,000 h·pg/mL; Cmax below approximately 80,000 pg/mL |
The 6 mg claim text supplied includes a second AUC range of approximately 730,000 to 1,142,000 h·pg/mL and a Cmax below approximately 36,800 pg/mL. Those values correspond numerically to the 48 mg ranges also recited in claim 27. The duplicated alternatives create a claim-construction issue and should be checked against the official patent file and any certificate of correction.
What is the FDA and Orange Book status?
FDA approved Austedo XR as a once-daily extended-release tablet containing deutetrabenazine. The approved strengths are 6 mg, 12 mg, 24 mg and 36 mg, with dosing that can be increased based on clinical response and tolerability. [1]
The original Austedo product is an immediate-release tablet administered twice daily. Austedo XR uses a different extended-release presentation and is the product most directly implicated by the osmotic dosage-form claims.
| Regulatory issue |
Assessment |
| Active ingredient |
Deutetrabenazine |
| Product associated with claimed technology |
Austedo XR |
| Dosage form |
Extended-release oral tablet |
| FDA approval |
Approved in 2023 |
| Approved indications |
Huntington's disease-associated chorea and tardive dyskinesia |
| Reference product pathway |
Small-molecule NDA |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
ANDA, subject to applicable patent certifications |
| Orange Book relevance |
Product and patent listing must be confirmed in the current FDA Orange Book |
An Orange Book listing does not establish patent validity. It can, however, create statutory notice and litigation consequences for an ANDA applicant that files a Paragraph IV certification. [2]
When does US 11,311,488 lose exclusivity?
The patent's term is governed by the earliest effective nonprovisional filing date, adjusted for any applicable patent-term adjustment and potentially affected by patent-term extension rules. The supplied claim text does not establish the controlling priority chain, patent-term adjustment, or any terminal disclaimer.
The patent issued on April 26, 2022. [3] Patent issuance does not determine expiration. A 20-year term normally runs from the effective US nonprovisional or international filing date, not from the issue date. The precise expiration date must be taken from the official patent record and any Orange Book listing.
Regulatory exclusivity is separate from patent exclusivity. Austedo XR's approval date establishes the starting point for FDA regulatory exclusivity calculations, but regulatory exclusivity does not necessarily match the patent term. [1, 4]
Which companies are challenging US 11,311,488?
The relevant competitive field includes generic manufacturers and developers of alternative once-daily deutetrabenazine products. A Paragraph IV challenge would be expected to target one or more of the following:
- Lack of infringement based on a different release mechanism.
- Invalidity for anticipation or obviousness.
- Indefiniteness of particle-size, viscosity or pharmacokinetic limitations.
- Written-description or enablement issues for broad Markush language.
- Inoperability of the claimed full dose range.
- Failure of the commercial product to meet every limitation.
No biosimilar challenge is relevant because deutetrabenazine is a chemically synthesized small molecule, not a biologic. Any abbreviated approval challenge would proceed through the ANDA framework rather than the biosimilar pathway.
A Paragraph IV notice would ordinarily trigger a 45-day period for the patent owner to file suit. Timely litigation can impose a statutory stay of FDA approval for up to 30 months, subject to statutory exceptions and court rulings. [5]
What patent litigation and settlement risks apply?
The key litigation question is whether a generic product has been formulated to meet the full combination in claim 1 or any asserted dependent claim.
Likely infringement evidence
A patent owner would examine:
- Tablet cross-section and layer structure.
- Membrane composition and thickness.
- Port diameter and placement.
- Drug-particle D10, D50 and D90 values.
- Immediate-release coating composition.
- Drug distribution by layer.
- Polymer viscosity and molecular weight.
- Osmotic-agent-to-polymer ratio.
- Dissolution results under the claimed conditions.
- Pharmacokinetic data from the ANDA's bioequivalence program.
Likely invalidity evidence
An ANDA applicant would likely search prior art covering:
- Push-pull osmotic tablets.
- Cellulose acetate membranes.
- Osmotic salts and polyethylene oxide layers.
- Deutetrabenazine particle engineering.
- Extended-release VMAT2 inhibitors.
- Dose-proportional exposure profiles.
- Immediate-release overcoats on controlled-release tablets.
A settlement could involve a licensed launch date, an authorized generic arrangement, a covenant not to sue, or a formulation redesign. The commercial impact would depend on the number of remaining patents protecting Austedo XR and the scope of any settlement release. A settlement concerning one patent would not necessarily remove other Orange Book barriers.
How does this patent compare with the original Austedo formulation?
| Attribute |
Austedo |
Austedo XR and US 11,311,488 |
| Dosing frequency |
Generally twice daily |
Once daily |
| Formulation objective |
Immediate-release exposure |
Controlled osmotic release |
| Primary patent risk |
Active ingredient, salts, uses and formulation patents |
Osmotic tablet, microparticle distribution and PK claims |
| Main commercial advantage |
Established product |
Reduced dosing frequency |
| Generic substitution issue |
Conventional ANDA substitution analysis |
Greater formulation-specific complexity |
| Biosimilar relevance |
None |
None |
The patent is strategically important because it protects a differentiated product presentation after the active ingredient had already been commercialized. Its value is concentrated in lifecycle management, adherence positioning and protection of once-daily dosing.
What generic launch scenarios exist?
Scenario 1: No close formulation copy
A generic applicant uses a non-osmotic extended-release technology. This could reduce literal infringement risk under claim 1, although method and performance claims would still require analysis.
Scenario 2: Osmotic formulation with altered particle size
A competitor uses the same general push-pull architecture but changes the D10, D50 or D90 distribution. The outcome would depend on whether the altered values fall outside every asserted range and whether equivalence is plausible.
Scenario 3: No immediate-release coating
Removing the external deutetrabenazine coating could avoid claims requiring that feature. The applicant would still face claim-construction questions because claim 1 describes the coating as optional, while claims 18 and 19 expressly require it.
Scenario 4: Product launches after patent expiry
This is the lowest litigation-risk pathway but delays market entry and preserves the reference product's commercial position until the relevant patent estate expires.
Scenario 5: Paragraph IV litigation and settlement
A successful challenge could permit an earlier launch. A settlement could establish a negotiated entry date before the latest patent expiration while preserving Teva's market share during the interim period.
Key Takeaways
- US 11,311,488 is a formulation and method patent for once-daily osmotic deutetrabenazine.
- Claim 1 requires a two-layer push-pull osmotic tablet, semipermeable membrane, port, microparticle size parameters and defined drug distribution.
- Claims 21 through 28 add treatment, pharmacokinetic and dissolution coverage.
- The patent is strongest against a close copy of the Austedo XR delivery system.
- A non-osmotic or materially different extended-release formulation may provide a credible design-around position.
- Deutetrabenazine is a small molecule, so biosimilar risk does not apply.
- Generic entry would proceed through an ANDA and could involve Paragraph IV certification and patent litigation.
- The exact expiration date requires confirmation from the official priority chain, patent-term adjustment record and current Orange Book listing.
- The supplied claim text contains a numerical duplication in the 6 mg and 48 mg pharmacokinetic alternatives that may require review of the issued patent and any correction certificate.
FAQs
Is US 11,311,488 a patent on deutetrabenazine itself?
No. The claims focus on a once-daily osmotic dosage form, its structural components, drug-particle distribution, release profile and methods of treatment.
Does the patent cover every once-daily deutetrabenazine tablet?
No. A competing once-daily product would need to satisfy the limitations of at least one asserted claim. A formulation using a different release mechanism may avoid literal infringement.
Can a generic company file an ANDA for deutetrabenazine before this patent expires?
It can file an ANDA with an appropriate patent certification. A Paragraph IV certification may lead to litigation and a potential 30-month FDA approval stay under the Hatch-Waxman framework. [5]
Are Austedo and Austedo XR protected by the same patent claims?
Not necessarily. Austedo and Austedo XR are different dosage forms. The claims supplied are directed principally to the once-daily osmotic extended-release presentation associated with Austedo XR.
Does a different deutetrabenazine particle size automatically avoid infringement?
No. It may avoid a literal particle-size limitation if the product falls outside the claimed ranges, but the complete claim must be analyzed and the doctrine of equivalents may remain relevant.
References
-
U.S. Food and Drug Administration. (2023). Austedo XR (deutetrabenazine) extended-release tablets: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
U.S. Patent and Trademark Office. (2022). United States Patent No. 11,311,488. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2024). Regulatory exclusivity and patent information for approved drug products. FDA, Center for Drug Evaluation and Research.
-
Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
